<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Peptides Defined</title><description>Educational peptide profile updates, terminology notes, and research-literacy summaries.</description><link>https://peptidesdefined.com/</link><language>en-us</language><item><title>LL-37 Peptide: Wound-Healing Evidence, Infection Claims, and Safety Limits</title><link>https://peptidesdefined.com/blog/ll-37-peptide-wound-healing-infection-safety-evidence/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/ll-37-peptide-wound-healing-infection-safety-evidence/</guid><description>A research-backed guide to LL-37 peptide claims, topical chronic-wound trials, antimicrobial biology, infection-marketing limits, FDA compounding cautions, and safety unknowns.</description><pubDate>Fri, 29 May 2026 00:00:00 GMT</pubDate><category>ll-37</category><category>cathelicidin</category><category>wound healing</category><category>antimicrobial peptide</category><category>safety</category></item><item><title>KPV Peptide for Gut Inflammation: Evidence, Oral Claims, and Safety Limits</title><link>https://peptidesdefined.com/blog/kpv-peptide-gut-inflammation-evidence-safety/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/kpv-peptide-gut-inflammation-evidence-safety/</guid><description>A cautious review of KPV peptide gut-inflammation claims, PepT1 biology, cell and animal evidence, oral-delivery research, adjacent human data, and FDA safety cautions.</description><pubDate>Fri, 29 May 2026 00:00:00 GMT</pubDate><category>kpv</category><category>gut inflammation</category><category>inflammatory bowel disease</category><category>pept1</category><category>safety</category></item><item><title>Ascension Peptides Review: COAs, Research-Use Limits, and What to Check Before Buying</title><link>https://peptidesdefined.com/blog/ascension-peptides-review-coa-research-use/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/ascension-peptides-review-coa-research-use/</guid><description>A practical Ascension Peptides review focused on product range, COA due diligence, research-use-only boundaries, buying checks, and when our referral link makes sense.</description><pubDate>Fri, 29 May 2026 00:00:00 GMT</pubDate><category>ascension peptides</category><category>peptide supplier review</category><category>coa</category><category>research use</category><category>affiliate</category></item><item><title>GHK-Cu for Skin and Hair: Topical Evidence, Injectable Risks, and Claim Limits</title><link>https://peptidesdefined.com/blog/ghk-cu-skin-hair-injectable-safety-evidence/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/ghk-cu-skin-hair-injectable-safety-evidence/</guid><description>A source-backed guide to GHK-Cu skin and hair claims, topical cosmetic evidence, human study limits, FDA compounding context, injectable-route risks, and how to read copper-peptide marketing.</description><pubDate>Thu, 28 May 2026 00:00:00 GMT</pubDate><category>ghk-cu</category><category>copper peptide</category><category>skin and hair</category><category>injectable safety</category><category>cosmetic evidence</category></item><item><title>MOTS-c Peptide for Weight Loss and Insulin Sensitivity: What the Evidence Shows</title><link>https://peptidesdefined.com/blog/mots-c-peptide-weight-loss-insulin-sensitivity-evidence/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/mots-c-peptide-weight-loss-insulin-sensitivity-evidence/</guid><description>A research-backed review of MOTS-c peptide weight-loss, insulin-sensitivity, exercise, and longevity claims, including preclinical findings, human biomarker studies, a 2026 Phase 2a trial record, and safety limits.</description><pubDate>Thu, 28 May 2026 00:00:00 GMT</pubDate><category>mots-c</category><category>insulin sensitivity</category><category>weight loss claims</category><category>exercise</category><category>mitochondria</category></item><item><title>SS-31 Peptide and Elamipretide: Barth Syndrome Approval vs Longevity Claims</title><link>https://peptidesdefined.com/blog/ss-31-elamipretide-mitochondria-longevity-claims/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/ss-31-elamipretide-mitochondria-longevity-claims/</guid><description>A research-backed guide to SS-31 and elamipretide, Forzinity&apos;s Barth syndrome approval, mitochondrial evidence, primary mitochondrial myopathy trial limits, safety warnings, and longevity claims.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><category>ss-31</category><category>elamipretide</category><category>mitochondria</category><category>longevity claims</category><category>safety</category></item><item><title>Thymosin Alpha-1 for Immune Support: Human Evidence, Sepsis Trials, and FDA Warnings</title><link>https://peptidesdefined.com/blog/thymosin-alpha-1-immune-support-evidence-safety/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/thymosin-alpha-1-immune-support-evidence-safety/</guid><description>A source-backed review of thymosin alpha-1 immune-support claims, TESTS phase 3 sepsis findings, older trial evidence, regional status, FDA compounding warnings, and safety limits.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><category>thymosin alpha-1</category><category>immune support</category><category>sepsis</category><category>compounding</category><category>safety</category></item><item><title>PT-141 Side Effects and Safety: What Bremelanotide Evidence Actually Shows</title><link>https://peptidesdefined.com/blog/pt-141-side-effects-safety-bremelanotide/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/pt-141-side-effects-safety-bremelanotide/</guid><description>A research-backed guide to PT-141 side effects, Vyleesi label warnings, HSDD trial outcomes, blood-pressure effects, nausea, pigmentation risk, and the difference between approved bremelanotide and research-market products.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><category>pt-141</category><category>bremelanotide</category><category>side effects</category><category>safety</category><category>hsdd</category></item><item><title>Kisspeptin for Fertility, Testosterone, and Libido: What Human Studies Actually Show</title><link>https://peptidesdefined.com/blog/kisspeptin-fertility-testosterone-libido-evidence/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/kisspeptin-fertility-testosterone-libido-evidence/</guid><description>A source-backed review of kisspeptin for fertility, testosterone, and libido claims, including human endocrine studies, IVF research, HSDD data, compounding risk warnings, and where evidence remains early.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><category>kisspeptin</category><category>fertility</category><category>testosterone</category><category>libido</category><category>research literacy</category></item><item><title>Tesamorelin for Visceral Fat: Evidence, Safety, and Weight-Loss Claim Limits</title><link>https://peptidesdefined.com/blog/tesamorelin-visceral-fat-weight-loss-evidence/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/tesamorelin-visceral-fat-weight-loss-evidence/</guid><description>A research-backed guide to tesamorelin for visceral fat, HIV-associated lipodystrophy evidence, liver-fat data, GLP-1 comparisons, safety warnings, and weight-loss claim limits.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><category>tesamorelin</category><category>visceral fat</category><category>hiv lipodystrophy</category><category>weight loss</category><category>growth hormone</category></item><item><title>Melanotan II Side Effects and Safety: What the Evidence Actually Shows</title><link>https://peptidesdefined.com/blog/melanotan-ii-side-effects-safety-evidence/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/melanotan-ii-side-effects-safety-evidence/</guid><description>A research-backed guide to Melanotan II side effects, tanning-peptide claims, small human studies, online-use data, regulator warnings, and case-report safety signals.</description><pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate><category>melanotan ii</category><category>side effects</category><category>safety</category><category>tanning peptide</category><category>research literacy</category></item><item><title>What Happens When You Stop GLP-1 Drugs? Weight Regain, Maintenance, and the Evidence</title><link>https://peptidesdefined.com/blog/what-happens-when-you-stop-glp-1-weight-regain-maintenance/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/what-happens-when-you-stop-glp-1-weight-regain-maintenance/</guid><description>A research-literacy guide to GLP-1 withdrawal and maintenance evidence from semaglutide STEP trials, tirzepatide SURMOUNT-4, and newer weight-regain analyses.</description><pubDate>Tue, 26 May 2026 00:00:00 GMT</pubDate><category>glp-1</category><category>maintenance</category><category>weight regain</category><category>semaglutide</category><category>tirzepatide</category></item><item><title>GLP-1 Side Effects and Safety Signals Explained</title><link>https://peptidesdefined.com/blog/glp-1-side-effects-safety-signals-explained/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/glp-1-side-effects-safety-signals-explained/</guid><description>A source-backed guide to common GLP-1 adverse effects and serious safety signals, including GI effects, thyroid warnings, gallbladder disease, pancreatitis, kidney injury, retinopathy, and compounded-product risks.</description><pubDate>Tue, 26 May 2026 00:00:00 GMT</pubDate><category>glp-1</category><category>safety</category><category>side effects</category><category>semaglutide</category><category>tirzepatide</category></item><item><title>Compounded Semaglutide and Tirzepatide in 2026: What the FDA Rules Actually Say</title><link>https://peptidesdefined.com/blog/compounded-semaglutide-tirzepatide-2026-fda-rules/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/compounded-semaglutide-tirzepatide-2026-fda-rules/</guid><description>A plain-English guide to GLP-1 compounding rules after shortage changes, including 503A, 503B, essentially-copy limits, salt forms, dosing errors, and red flags.</description><pubDate>Mon, 25 May 2026 00:00:00 GMT</pubDate><category>glp-1</category><category>compounding</category><category>regulatory literacy</category><category>semaglutide</category><category>tirzepatide</category></item><item><title>CJC-1295 vs Ipamorelin vs Sermorelin vs Tesamorelin: Growth-Hormone Peptides Compared</title><link>https://peptidesdefined.com/blog/cjc-1295-ipamorelin-sermorelin-tesamorelin-growth-hormone-peptides/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/cjc-1295-ipamorelin-sermorelin-tesamorelin-growth-hormone-peptides/</guid><description>A source-aware comparison of growth-hormone peptide topics across receptor biology, evidence strength, FDA status, compounding safety concerns, and marketing claims.</description><pubDate>Mon, 25 May 2026 00:00:00 GMT</pubDate><category>comparison</category><category>growth hormone</category><category>cjc-1295</category><category>ipamorelin</category><category>tesamorelin</category></item><item><title>Retatrutide vs Tirzepatide vs Semaglutide: Trial Evidence, Status, and What Is Actually Different</title><link>https://peptidesdefined.com/blog/retatrutide-vs-tirzepatide-vs-semaglutide/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/retatrutide-vs-tirzepatide-vs-semaglutide/</guid><description>A research-backed comparison of retatrutide, tirzepatide, and semaglutide across receptor targets, approval status, obesity trials, cardiometabolic evidence, and open questions.</description><pubDate>Mon, 25 May 2026 00:00:00 GMT</pubDate><category>comparison</category><category>glp-1</category><category>retatrutide</category><category>tirzepatide</category><category>semaglutide</category></item><item><title>Peptide Reconstitution Math Explained: mg, mcg, mL, Units, and Concentration</title><link>https://peptidesdefined.com/blog/peptide-reconstitution-math-mg-mcg-ml-units/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/peptide-reconstitution-math-mg-mcg-ml-units/</guid><description>A measurement-first guide to peptide reconstitution math, including concentration, milligrams, micrograms, milliliters, syringe units, and common calculation mistakes.</description><pubDate>Mon, 25 May 2026 00:00:00 GMT</pubDate><category>reconstitution</category><category>units</category><category>calculator</category><category>measurement literacy</category></item><item><title>Approved vs Investigational vs Compounded vs Research Peptides</title><link>https://peptidesdefined.com/blog/approved-investigational-compounded-research-peptides/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/approved-investigational-compounded-research-peptides/</guid><description>A practical framework for separating FDA-approved peptide medicines, clinical-stage investigational drugs, compounded products, and research peptides sold online.</description><pubDate>Sun, 24 May 2026 00:00:00 GMT</pubDate><category>regulatory literacy</category><category>evidence</category><category>compounding</category></item><item><title>BPC-157 vs TB-500 vs GHK-Cu: Recovery Peptides and the Evidence Gap</title><link>https://peptidesdefined.com/blog/bpc-157-vs-tb-500-vs-ghk-cu/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/bpc-157-vs-tb-500-vs-ghk-cu/</guid><description>A source-backed comparison of three popular recovery peptide topics, with a focus on what is human evidence, what is preclinical, and where marketing gets ahead of the data.</description><pubDate>Sun, 24 May 2026 00:00:00 GMT</pubDate><category>comparison</category><category>recovery</category><category>evidence</category></item><item><title>GLP-1, GIP, Glucagon, and Amylin Peptides Compared</title><link>https://peptidesdefined.com/blog/glp-1-gip-glucagon-amylin-peptides-compared/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/glp-1-gip-glucagon-amylin-peptides-compared/</guid><description>A source-backed comparison of semaglutide, tirzepatide, retatrutide, cagrilintide, and related incretin or amylin-based peptide medicines.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>comparison</category><category>glp-1</category><category>incretins</category></item><item><title>GLP-1 Drugs vs Other Peptides: What Makes the Evidence Different</title><link>https://peptidesdefined.com/blog/glp-1-drugs-vs-other-peptides/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/glp-1-drugs-vs-other-peptides/</guid><description>A practical comparison of approved GLP-1 and incretin drugs, other approved peptide medicines, and research-market peptides with thinner evidence.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>comparison</category><category>evidence</category><category>research literacy</category></item><item><title>How to Read a Peptide Study</title><link>https://peptidesdefined.com/blog/how-to-read-a-peptide-study/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/how-to-read-a-peptide-study/</guid><description>A practical guide to reading peptide research without overinterpreting study design, endpoints, controls, safety reporting, or early animal and cell data.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>research literacy</category><category>evidence</category><category>safety</category></item><item><title>Introducing Peptides Defined</title><link>https://peptidesdefined.com/blog/introducing-peptides-defined/</link><guid isPermaLink="true">https://peptidesdefined.com/blog/introducing-peptides-defined/</guid><description>A short note from the PD Team on why Peptides Defined exists, how we plan to cover peptide topics, and what readers can expect next.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>team note</category><category>editorial</category></item><item><title>TB-500 - Research peptide</title><link>https://peptidesdefined.com/peptides/recovery/tb-500/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/recovery/tb-500/</guid><description>A commonly searched peptide topic that needs careful separation between research context, informal claims, and evidence quality.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Recovery</category><category>research literacy</category><category>claims review</category></item><item><title>BPC-157 - Research peptide</title><link>https://peptidesdefined.com/peptides/recovery/bpc-157/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/recovery/bpc-157/</guid><description>Often discussed online, making it a good candidate for a source-first overview of terminology, study types, and limitations.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Recovery</category><category>terminology</category><category>evidence context</category></item><item><title>GHK-Cu - Copper peptide</title><link>https://peptidesdefined.com/peptides/skin-hair/ghk-cu/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/skin-hair/ghk-cu/</guid><description>A peptide frequently associated with skin-care and biology discussions, suited for a plain-English ingredient and research explainer.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Skin &amp; Hair</category><category>skin research</category><category>ingredient literacy</category></item><item><title>CJC-1295 - Modified peptide</title><link>https://peptidesdefined.com/peptides/hormone-signaling/cjc-1295/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/hormone-signaling/cjc-1295/</guid><description>A topic where readers benefit from clear definitions around analogs, mechanisms discussed in research, and claim strength.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Hormone Signaling</category><category>analog basics</category><category>mechanism notes</category></item><item><title>Ipamorelin - Peptide analog</title><link>https://peptidesdefined.com/peptides/hormone-signaling/ipamorelin/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/hormone-signaling/ipamorelin/</guid><description>A useful future profile for explaining receptor language, research endpoints, and why casual summaries can overstate findings.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Hormone Signaling</category><category>receptors</category><category>study design</category></item><item><title>Semaglutide - Peptide-based medicine</title><link>https://peptidesdefined.com/peptides/weight-loss/semaglutide/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/weight-loss/semaglutide/</guid><description>A familiar example for explaining how peptide-related molecules can appear in regulated medical contexts as well as public discussion.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Weight Loss</category><category>regulated medicine</category><category>public claims</category></item><item><title>Tirzepatide - Peptide-based medicine</title><link>https://peptidesdefined.com/peptides/weight-loss/tirzepatide/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/weight-loss/tirzepatide/</guid><description>A dual-incretin medicine often discussed in weight-management contexts, useful for explaining regulated therapies versus casual peptide marketing.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Weight Loss</category><category>regulated medicine</category><category>metabolic research</category></item><item><title>Retatrutide - Investigational peptide medicine</title><link>https://peptidesdefined.com/peptides/weight-loss/retatrutide/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/weight-loss/retatrutide/</guid><description>An investigational once-weekly triple hormone receptor agonist being studied across obesity, type 2 diabetes, and related cardiometabolic conditions.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Weight Loss</category><category>clinical trials</category><category>triple agonist</category><category>metabolic research</category></item><item><title>Cagrilintide - Investigational peptide analog</title><link>https://peptidesdefined.com/peptides/weight-loss/cagrilintide/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/weight-loss/cagrilintide/</guid><description>A long-acting amylin analog candidate that is often discussed alongside metabolic research and combination-therapy headlines.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Weight Loss</category><category>amylin analog</category><category>clinical trials</category></item><item><title>Tesamorelin - Peptide-based medicine</title><link>https://peptidesdefined.com/peptides/metabolic-health/tesamorelin/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/metabolic-health/tesamorelin/</guid><description>A regulated peptide medicine topic that can help readers understand indication-specific approvals and why context matters.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Metabolic Health</category><category>regulated medicine</category><category>indication context</category></item><item><title>MOTS-c - Mitochondrial-derived peptide</title><link>https://peptidesdefined.com/peptides/metabolic-health/mots-c/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/metabolic-health/mots-c/</guid><description>A mitochondrial-derived peptide discussed in metabolism research, suited for explaining early-stage evidence and mechanistic claims.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Metabolic Health</category><category>metabolism</category><category>mechanism notes</category></item><item><title>Thymosin Alpha-1 - Immune-signaling peptide</title><link>https://peptidesdefined.com/peptides/immune-signaling/thymosin-alpha-1/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/immune-signaling/thymosin-alpha-1/</guid><description>An immune-signaling peptide topic where geography, product status, and evidence context need careful explanation.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Immune Signaling</category><category>immune research</category><category>regional status</category></item><item><title>KPV - Tripeptide fragment</title><link>https://peptidesdefined.com/peptides/immune-signaling/kpv/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/immune-signaling/kpv/</guid><description>A short peptide fragment often discussed in inflammation-related research, making it a useful source-literacy profile.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Immune Signaling</category><category>inflammation research</category><category>source literacy</category></item><item><title>LL-37 - Antimicrobial peptide</title><link>https://peptidesdefined.com/peptides/immune-signaling/ll-37/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/immune-signaling/ll-37/</guid><description>An antimicrobial peptide topic that benefits from careful discussion of biological roles versus therapeutic claims.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Immune Signaling</category><category>antimicrobial peptide</category><category>biology context</category></item><item><title>Melanotan II - Peptide analog</title><link>https://peptidesdefined.com/peptides/pigmentation/melanotan-ii/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/pigmentation/melanotan-ii/</guid><description>A commonly searched analog where safety, legality, and informal use claims require especially careful review before publication.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Pigmentation</category><category>safety review needed</category><category>public claims</category></item><item><title>Bremelanotide - Peptide-based medicine</title><link>https://peptidesdefined.com/peptides/hormone-signaling/bremelanotide/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/hormone-signaling/bremelanotide/</guid><description>A regulated melanocortin-receptor medicine topic useful for distinguishing approved use from broader online peptide discussion.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Hormone Signaling</category><category>regulated medicine</category><category>receptor biology</category></item><item><title>Kisspeptin - Hormone-signaling peptide</title><link>https://peptidesdefined.com/peptides/hormone-signaling/kisspeptin/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/hormone-signaling/kisspeptin/</guid><description>A hormone-signaling peptide family often discussed in reproductive-axis research and endocrine source summaries.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Hormone Signaling</category><category>endocrine research</category><category>receptor biology</category></item><item><title>SS-31 - Mitochondria-targeted peptide</title><link>https://peptidesdefined.com/peptides/mitochondrial/ss-31/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/mitochondrial/ss-31/</guid><description>A mitochondria-targeted peptide topic suited for explaining trial-stage research, mechanisms, and claim limitations.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Mitochondrial</category><category>mitochondria</category><category>clinical trials</category></item><item><title>Epitalon - Synthetic peptide</title><link>https://peptidesdefined.com/peptides/longevity/epitalon/</link><guid isPermaLink="true">https://peptidesdefined.com/peptides/longevity/epitalon/</guid><description>A longevity-adjacent peptide topic where readers need careful distinction between mechanistic discussion and human outcome claims.</description><pubDate>Sat, 23 May 2026 00:00:00 GMT</pubDate><category>Longevity</category><category>longevity claims</category><category>evidence context</category></item></channel></rss>